Empagliflozin,
does it really help with Reduced cardiovascular death or heart-failure hospitalization in chronic heart failure with ejection fraction above 40%?
research showsThe grade is B. EMPEROR-Preserved analyzed all 5,988 randomized participants and found cardiovascular death or first heart-failure hospitalization in 13.8% versus 17.1%, HR 0.79 (95% CI 0.69 to 0.90), P<0.001. Heart-failure hospitalization fell, HR 0.71 (95% CI 0.60 to 0.83), but cardiovascular death did not, HR 0.91 (0.76 to 1.09). This was the single manufacturer-funded confirmatory empagliflozin trial in this indication, giving B with 76 points.
ads claimMarketing should describe reduced hospitalization or worsening in this population, not merely say the drug is good for the heart. Composite benefit and cardiovascular death alone must remain separate.
Useful facts when choosing a product
- The tested empagliflozin dose was 10 mg once daily.
- Both pivotal trials enrolled chronic heart-failure patients with ejection fraction above 40%.
- EMPEROR-Preserved and DELIVER were sponsored by different manufacturers.
Chamgap Semantic Classification Code
Candidate index · review held
M.empagliflozin.UNK.cardiovascular-death-or-heart-failure-hospitalization-in-chronic-heart-failure-with-ejection-fraction-above-40-percent.reduce.placeboMedicinal interventions > Empagliflozin > Unknown > cardiovascular death or heart-failure hospitalization in chronic heart failure with ejection fraction above 40% > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
EMPEROR-Preserved randomized 5,988 patients with ejection fraction above 40%, 2,997 to empagliflozin and 2,991 to placebo, and analyzed all participants. Over 26.2 months, 415 (13.8%) versus 511 (17.1%) had a primary event. Heart-failure hospitalization occurred in 259 (8.6%) versus 352 (11.8%), HR 0.71 (95% CI 0.60 to 0.83), while cardiovascular death had HR 0.91 (0.76 to 1.09) and was not significant. This was the single manufacturer-funded confirmatory empagliflozin trial in this indication; DELIVER is class-supporting evidence for a different drug and shared some investigators.
Why this is classified as B (76)
Two large trials from different drug and sponsor programs consistently reduced clinical heart-failure events, but overlapping authors give B with 76 points.
Counterpoint. This grade applies to the composite clinical outcome in preserved or mildly reduced ejection fraction, not cardiovascular death alone.
Rejudgment record. Cross-check applied — Two large blinded all-randomized trials reduced clinical heart-failure events, but several authors overlapped
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced cardiovascular death or heart-failure hospitalization | B | EMPEROR-Preserved found HR 0.79, and DELIVER reproduced the class effect on clinical events. |
| Reduced cardiovascular death alone | D | The composite benefit was driven mainly by heart-failure hospitalization and cannot be expanded to mortality alone. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Anker SD et al. 2021 EMPEROR-Preserved | Multinational double-blind placebo-controlled event-driven randomized trial | 5,988 randomized, 2,997 versus 2,991, with all 5,988 analyzed | Boehringer Ingelheim and Eli Lilly | Cardiovascular death or first heart-failure hospitalization | 13.8% versus 17.1%; HR 0.79 (95% CI 0.69 to 0.90), P<0.001 | Pivotal large clinical-event evidence |
| Solomon SD et al. 2022 DELIVER | Multinational double-blind placebo-controlled event-driven randomized trial | 6,263 randomized and analyzed | AstraZeneca | Cardiovascular death or worsening heart failure | 16.4% versus 19.5%; HR 0.82 (95% CI 0.73 to 0.92), P<0.001 | Large replication with another SGLT2 inhibitor |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-01).
Final verification and publication gate: Codex · Evidence date: 2026-08-01 · Corrections: none
Cite this verdict
[Chamgap] Empagliflozin x cardiovascular death or hospitalization in heart failure with preserved ejection fraction — Evidence Grade B·76. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/empagliflozin-hfpef-cardiovascular-death-heart-failure-hospitalization/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.